Coya Therapeutics (COYA) to Release Earnings on Wednesday

Coya Therapeutics (NASDAQ:COYA) is expected to release its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect Coya Therapeutics to post earnings of $0.02 per share and revenue of $3.6970 million for the quarter. Investors can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Wednesday, November 12, 2025 at 8:00 AM ET.

Coya Therapeutics (NASDAQ:COYA) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.14). The business had revenue of $0.16 million for the quarter, compared to analyst estimates of $0.78 million. On average, analysts expect Coya Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Coya Therapeutics Price Performance

COYA opened at $6.00 on Tuesday. Coya Therapeutics has a 1-year low of $4.65 and a 1-year high of $8.29. The firm has a market cap of $100.44 million, a P/E ratio of -4.84 and a beta of 0.20. The company has a 50 day simple moving average of $6.20 and a two-hundred day simple moving average of $6.06.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Chardan Capital restated a “buy” rating and set a $14.00 target price on shares of Coya Therapeutics in a research report on Wednesday, September 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Coya Therapeutics in a research note on Wednesday, October 8th. D. Boral Capital reaffirmed a “buy” rating and set a $18.00 price target on shares of Coya Therapeutics in a research note on Monday, September 29th. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of Coya Therapeutics in a research note on Monday, August 25th. Finally, BTIG Research reissued a “buy” rating and issued a $15.00 target price on shares of Coya Therapeutics in a research note on Tuesday, September 30th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Coya Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $16.20.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Coya Therapeutics stock. Jane Street Group LLC raised its holdings in shares of Coya Therapeutics, Inc. (NASDAQ:COYA) by 101.7% during the first quarter, according to its most recent filing with the SEC. The firm owned 26,137 shares of the company’s stock after purchasing an additional 13,176 shares during the period. Jane Street Group LLC owned 0.16% of Coya Therapeutics worth $169,000 at the end of the most recent reporting period. 39.75% of the stock is owned by hedge funds and other institutional investors.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.